<DOC>
	<DOCNO>NCT01361464</DOCNO>
	<brief_summary>This phase II trial study well tipifarnib work treat old patient acute myeloid leukemia . Tipifarnib may stop growth cancer cell block enzymes need cell growth .</brief_summary>
	<brief_title>Tipifarnib Treating Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine complete remission ( CR ) rate acute myeloid leukemia ( AML ) patient prospectively select tipifarnib ( ZARNESTRA ) treatment basis 2-gene signature ( RASGRP1 : APTX ratio ) bone marrow aspirate . SECONDARY OBJECTIVES : I . To determine median overall 1-year survival patient treat regimen II . To determine median relapse-free survival patient treat regimen . III . To determine safety regimen patient IV . To determine immunophenotypic expression RASGRP1 baseline bone marrow blast assess correlation PCR-based detection . OUTLINE : This multicenter study . Patients receive tipifarnib orally twice daily day 1-21 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Bone marrow aspirate and/or biopsy collect baseline day 28 course 1 2 RasGRP1 protein expression analysis qRT-PCR . After completion study therapy , patient follow every 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>Previously untreated acute myeloid leukemia ( AML ) ( de novo secondary ) No diagnosis acute promyelocytic leukemia ( APL ) Deemed unsuitable refuse standard induction chemotherapy RASGRP1 : APTX ratio &gt; = 5 , bone marrow screen No patient know leukemic involvement central nervous system ECOG performance status = &lt; 2 No WBC &gt; = 30,000/uL ( hydroxyurea permit 24 hour prior initiation therapy ) Serum creatinine less 1.5 time upper limit normal range ( ULN ) ( National Cancer Institute [ NCI ] Common Toxicity Criteria [ CTC ] Grade 1 ) Total bilirubin less 1.5 time ULN ( unless increase unequivocally due hemolysis Gilbert syndrome ) ALT AST less 2.5 time ULN ( NCI CTC Grade 1 ) Men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation No symptomatic neuropathy grade 2 bad No uncompensated disseminate intravascular coagulation ( DIC ) uncontrolled bleed No history allergic reaction attribute compound similar chemical biologic composition tipifarnib ( R115777 ) , imidazole drug , include clotrimazole , ketoconazole , miconazole , econazole , fenticonazole , isoconazole , sulconazole , ticonazole , terconazole No uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Known HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction R115777 ; addition , patient increase risk lethal infection treat marrowsuppressive therapy ; know HIVpositive patient NOT antiretroviral therapy AND CD4 cell count &gt; = 400/mm^3 eligible No concurrent cytotoxic biologic antileukemic therapy No patient receive investigational agent Use enzymeinducing anticonvulsant ( e.g. , phenytoin , fosphenytoin , phenobarbital , primidone , carbamazepine , oxcarbazepine ) take tipifarnib ( R115777 ) contraindicate If clinically indicate , subject may use nonenzymeinducing anticonvulsant treatment R115777</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>